PEDIATRIC NEUROLOGY BRIEFS

A MONTHLY JOURNAL REVIEW

Vol. 30, No. 9

September 2016

Editor

John J. Millichap, MD

Founding Editor

J. Gordon Millichap, MD

Editorial Advisory Board

Leon G. Epstein, MD

Douglas R. Nordli, Jr., MD

Contributing Editors (2016)

José Biller, MD

Chelsea Chambers, MS, CGC

Melissa G. Chung, MD

Radhika Dhamija, MD

Amy A. Gelfand, MD, MAS

Cecil D. Hahn, MD, MPH

Chafic Karam, MD

Marisa Klein-Gitelman, MD

Lawrence J. Jennings, MD, PhD

Anthony P. Kontos, PhD

Cynthia R. LaBella, MD

Srishti Nangia, MD

Dragos A. Nita, MD, PhD

Andrea C. Pardo, MD

Colin Quinn, MD

Vamshi K. Rao, MD

David G. Ritacco, MD, PhD

Maura Ryan, MD

Rochelle Sweis, DO

Martin Tisdall, FRCS, MD

Molly Tracy, MD

Sophia Varadkar, MRCPI, PhD

Michelle M. Yee, CPNP

GENETIC DISORDERS

Genetic Testing Requires NGS and Sanger Methodologies

36

Lawrence J. Jennings, MD, PhD and Dawn Kirschmann, PhD

Pediatr Neurol Briefs 2016;30(9):36. <http://dx.doi.org/10.15844/pedneurbriefs-30-9-1>

CC BY 4.0 | OPEN ACCESS

PEDIATRIC NEUROLOGY BRIEFS © 1987-2016, ISSN 1043-3155 (print) 2166-6482 (online), is published monthly by Pediatric Neurology Briefs Publishers, PO Box 11391, Chicago, IL 60611. This work is licensed under the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. **Mission:** Pediatric Neurology Briefs is an Open Access (OA) continuing education service designed to expedite and facilitate the review of current scientific information for physicians and other health professionals. **Disclaimer:** While the information is believed to be true and accurate at publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any error or omissions. The publisher makes no warranty, express or implied, with respect to the material contained herein. Visit Pediatric Neurology Briefs online: <http://www.pediatricneurologybriefs.com>. Current Issue DOI: <http://dx.doi.org/10.15844/pedneurbriefs-30-9>

GENETIC DISORDERS**Genetic Testing Requires NGS and Sanger Methodologies**Lawrence J. Jennings, MD, PhD¹* and Dawn Kirschmann, PhD¹¹Department of Pathology and Laboratory Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL*Correspondence: Dr. Lawrence J. Jennings, E-mail: ljennings@luriechildrens.org**Related Article:** Djémié T, Weckhuysen S, von Spiczak S, Carvill GL, Jaehn J, Anttonen AK et al.; EuroEPINOMICS-RES Dravet working group. Pitfalls in genetic testing: the story of missed SCN1A mutations. *Mol Genet Genomic Med* 2016 Apr;4(4):457–64.**Keywords:** NGS; Sanger; SCN1A

Investigators from the EuroEPINOMICS rare epilepsy syndromes Dravet working group performed whole-exome sequencing on 31 trios that had been reported negative for SCN1A mutations by Sanger sequencing. They found 8 probands had de novo variants in SCN1A. A survey of 16 genetic centers identified 20 additional probands that had been initially reported as negative by Sanger sequencing but positive by NGS. The investigators present an overview of the reasons for false negative results obtained by Sanger sequencing. Of the 21 cases with a known cause, “human error” was the most common (primarily misread sequence and sample switch). [1]

COMMENTARY. When compared to Sanger sequencing, there are some important advantages to NGS that the investigators mention. Most obviously, NGS allows the acquisition of more sequence data for a lower cost. Mutations in several genes have now been associated with Dravet syndrome (e.g. PCDH19, GABRG2, CHD2, and HCN1), and Sanger sequencing multiple genes can be costly and time-consuming. Also, if trios are performed de novo variants can readily be identified and implicated. This was demonstrated in one intronic variant that was not called initially although seen at the time of Sanger sequencing. NGS data also gives reads on single alleles. Therefore, insertion and deletion variants on the second allele or in the intron do not interfere with the sequence interpretation. This was demonstrated in another case in which an intronic deletion precluded an accurate interpretation of the Sanger sequence data. Also, NGS has the potential to detect mosaicism better than Sanger sequencing which has a limit of detection of 10–20% variant allele [2]. This was demonstrated in a third case in which the mutant peak on Sanger electropherograms were present but too low and misread. Of course, NGS detection of mosaicism depends on the number of reads at that position and the thresholds for calling a variant. NGS sequencing generally is not intended to have the depth to confidently exclude germline mosaicism [3].

This study highlights some problems with Sanger sequencing with the most common error being the misreading of Sanger electropherogram traces by technologists. Reading Sanger sequences can be challenging and requires a high degree of skill and concentration; however, the use of software tools that identify variants for technologist review

are available. Such tools can greatly reduce the risk of these types of error. In contrast, poor primer design and sample switch errors are not specific to Sanger sequencing.

We should also note what this study does not tell us. This study is not a comparison of NGS and Sanger sequencing. The authors stated that “our data show that Sanger sequencing resulted in 28 false-negative results while NGS missed one mutation”, which is potentially misleading out of context. By the design of the study, these investigators looked for false-negative results in cases initially screened by Sanger sequencing so understandably that is what they found. A single case that was initially screen positive by Sanger sequencing but negative 8 years later by NGS is included as well, perhaps to highlight a technical limitation of NGS.

Currently, Sanger sequencing is often used to address some of the limitations of NGS such as low-coverage, repetitive sequence, pseudogenes, homopolymer repeats, and large insertions and deletions [3]. These two technologies complement each other and can be used very effectively together. It is important to know what exactly it being sequenced and what are the limitations to each methodology.

Disclosures

The author(s) have declared that no competing interests exist.

References

1. Djémié T, Weckhuysen S, von Spiczak S, Carvill GL, Jaehn J, Anttonen AK et al.; EuroEPINOMICS-RES Dravet working group. Pitfalls in genetic testing: the story of missed SCN1A mutations. *Mol Genet Genomic Med* 2016 Apr;4(4):457–64. <http://dx.doi.org/10.1002/mgg3.217> PMID:27465585
2. Jennings LJ, Yu M, Zhou L, Rand CM, Berry-Kravis EM, Weese-Mayer DE. Comparison of PHOX2B testing methods in the diagnosis of congenital central hypoventilation syndrome and mosaic carriers. *Diagn Mol Pathol* 2010 Dec;19(4):224–31. <http://dx.doi.org/10.1097/PDM.0b013e3181eb92ff> PMID:21051998
3. Schrijver I, Aziz N, Farkas DH, Furtado M, Gonzalez AF, Greiner TC et al. Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. *J Mol Diagn* 2012 Nov;14(6):525–40. <http://dx.doi.org/10.1016/j.jmoldx.2012.04.006> PMID:22918138